Executive Summary
NIH's $115M award to Hensel Phelps for the Building B Vivarium at RML underscores robust federal investment in biomedical research infrastructure. Outlays of $119M exceeding the $115M obligation signal potential scope changes, boosting revenue visibility but highlighting execution risks. Investors should monitor extension to 2025-03-28 amid firm fixed price cost pressures.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All HHS Contracts digest from April 01, 2026.
Investment Signals (1)
- NIH $115M Vivarium Construction Win (HIGH)▲
$115M firm fixed price delivery order to Hensel Phelps for Building B at RML, with $119M outlays confirming cash flow momentum.
Risk Flags (1)
- Execution [HIGH RISK]▼
Outlays $119M > $115M obligation; firm fixed price exposes contractor to overruns; extension from 2024-07-31 to 2025-03-28 flags delays.
Opportunities (1)
- ◆
Performance extension to 2025-03-28; NIH pipeline in vivarium projects (PSC Y1JZ).
Sector Themes (1)
- ◆
Full and open competition award for $115M vivarium at RML highlights sustained federal capex in research facilities.
Watch List (2)
- 👁
{"entity"=>"Hensel Phelps Construction Co", "reason"=>"$115M NIH contract with $4M outlay overrun and extension potential.", "trigger"=>"obligation adjustments or new awards >$50M"}
- 👁
{"entity"=>"NIH RML Vivarium Projects", "reason"=>"Unusual outlay excess signals scope growth in biomedical construction.", "trigger"=>"additional PSC Y1JZ obligations"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All HHS Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals